Real World Evidence Solutions Market By Components (Data Sets, Consulting Services), By Application (Market Access and Reimbursement Coverage Decisions, Drug Development and Approvals, Post Market Surveillance, Medical Device Development and Approvals, Others), By End User (Pharmaceutical and Medical Device Companies, Healthcare Payers, Healthcare Providers, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031
The global real-world evidence solutions market was valued at $1,369.3 million in 2021, and is projected to reach $4,993.24 million by 2031, registering a CAGR of 13.7% from 2022 to 2031. Real-world evidence is defined as the healthcare data derived from a variety of non-traditional clinical research settings, such as electronic medical records (EMRs), claims and billing information, product and disease registries, and information collected by mobile devices and health apps.
The four main sources of collecting real-time data are administrative/claims data, clinical data, patient-generated or reported data, and emerging data sources including social media and cross-industry data collaborations such as Project Data Sphere. It is most commonly used by pharmaceutical companies, payers, and providers to better manage their organizations and make decisions about cost-effectiveness and comparative efficacy where other more robust data sources do not exist.
The key factors that drive the growth of the market are increase in the prevalence of cancer and chronic diseases, which increase the demand for the development of novel drugs and medical devices across the world. In addition, rise in adoption of technological advanced real-world evidence solutions; and increase in number of pipeline drugs are the key factors that further boost the growth of market. Moreover, rise in R&D activity rates, government initiatives, improved healthcare infrastructure, and increased funding for research projects across the world further propel the growth of the market.
In addition, increase in number of key players and the strategies adopted by them, and rise in demand for technologically advanced medical devices to conduct real time surveys and clinical trials propel the growth of the real-world evidence solutions market.
However, lack of awareness and reluctance to rely on real-world data hamper the market growth. Furthermore, high growth potential in developing economies and growth in focus on end-to-end real-world evidence services are expected to provide lucrative opportunity for the growth of real-world evidence solutions market during the forecast period.
The real-world evidence solutions market is segmented on the basis of component, application, end user, and region. By component it is segmented into datasets and consulting services. By application, it is segmented into market access & reimbursement/coverage decisions, drug development and approvals, post market surveillance, medical device development and approvals and others. By end user, it is segmented into pharmaceutical and medical device companies, healthcare providers, payers and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
North America accounted for a majority of the real-world evidence solutions market share in 2021 and is anticipated to remain dominant during the forecast period, owing to increase in demand for real-world evidence-based solutions or services, shift toward value-based healthcare instead of volume and the strategies adopted by key players for their product development.
Asia-Pacific was the second largest contributor to the market in 2021, and is expected to register the fastest CAGR during the forecast period, owing to rise in geriatric population, increase in number of cancer patients and an emerging economy.
The key players that operate in the real-world evidence solutions market are Clarivate PLC, Clinigen Group PLC, Cognizant Technology Solution Corporation, Elevance Health Inc., Flatiron Health, IBM Corporation, ICON PLC, IQVIA, Medpace Holding Corporation, Oracle Corporation, Parexel International Corporation, Perkin Elmer Inc., SAS Institute Inc., Symphony Innovation LLC, and Syneos Health Inc
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the real world evidence solutions market analysis from 2021 to 2031 to identify the prevailing real world evidence solutions market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the real world evidence solutions market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global real world evidence solutions market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Components
Data Sets
Type
Disparate Datasets
Integrated Datasets
Consulting Services
By Application
Market Access and Reimbursement Coverage Decisions
Drug Development and Approvals
Type
Oncology
Neurology
Immunology
Cardiovascular Diseases
Others
Post Market Surveillance
Medical Device Development and Approvals
Others
By End User
Pharmaceutical and Medical Device Companies
Healthcare Payers
Healthcare Providers
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest Of Asia Pacifc
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Clinigen Group plc
Cognizant Technology Solutions Corp.
Clarivate plc
IBM Corporation
Elevance Health Inc
Flatiron Health
ICON PLC
IQVIA
Medpace Holding Corporation
Oracle Corporation
Parexel International Corporation
Perkin Elmer Inc
SAS Institute Inc
Symphony Innovation LLC
Syneos Health Inc
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- CHAPTER 4: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENTS
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Data Sets
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.2.4 Data Sets Real World Evidence Solutions Market by Type
- 4.2.4.1 Disparate Datasets Market size and forecast, by region
- 4.2.4.2 Integrated Datasets Market size and forecast, by region
- 4.3 Consulting Services
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- CHAPTER 5: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Market Access and Reimbursement Coverage Decisions
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.3 Drug Development and Approvals
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- 5.3.4 Drug Development and Approvals Real World Evidence Solutions Market by Type
- 5.3.4.1 Oncology Market size and forecast, by region
- 5.3.4.2 Neurology Market size and forecast, by region
- 5.3.4.3 Immunology Market size and forecast, by region
- 5.3.4.4 Cardiovascular Diseases Market size and forecast, by region
- 5.3.4.5 Others Market size and forecast, by region
- 5.4 Post Market Surveillance
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
- 5.5 Medical Device Development and Approvals
- 5.5.1 Key market trends, growth factors and opportunities
- 5.5.2 Market size and forecast, by region
- 5.5.3 Market analysis by country
- 5.6 Others
- 5.6.1 Key market trends, growth factors and opportunities
- 5.6.2 Market size and forecast, by region
- 5.6.3 Market analysis by country
- CHAPTER 6: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Pharmaceutical and Medical Device Companies
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.3 Healthcare Payers
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- 6.4 Healthcare Providers
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country
- 6.5 Others
- 6.5.1 Key market trends, growth factors and opportunities
- 6.5.2 Market size and forecast, by region
- 6.5.3 Market analysis by country
- CHAPTER 7: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Components
- 7.2.2.1 North America Data Sets Real World Evidence Solutions Market by Type
- 7.2.3 North America Market size and forecast, by Application
- 7.2.3.1 North America Drug Development and Approvals Real World Evidence Solutions Market by Type
- 7.2.4 North America Market size and forecast, by End User
- 7.2.5 North America Market size and forecast, by country
- 7.2.5.1 U.S.
- 7.2.5.1.1 Market size and forecast, by Components
- 7.2.5.1.2 Market size and forecast, by Application
- 7.2.5.1.3 Market size and forecast, by End User
- 7.2.5.2 Canada
- 7.2.5.2.1 Market size and forecast, by Components
- 7.2.5.2.2 Market size and forecast, by Application
- 7.2.5.2.3 Market size and forecast, by End User
- 7.2.5.3 Mexico
- 7.2.5.3.1 Market size and forecast, by Components
- 7.2.5.3.2 Market size and forecast, by Application
- 7.2.5.3.3 Market size and forecast, by End User
- 7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Components
- 7.3.2.1 Europe Data Sets Real World Evidence Solutions Market by Type
- 7.3.3 Europe Market size and forecast, by Application
- 7.3.3.1 Europe Drug Development and Approvals Real World Evidence Solutions Market by Type
- 7.3.4 Europe Market size and forecast, by End User
- 7.3.5 Europe Market size and forecast, by country
- 7.3.5.1 Germany
- 7.3.5.1.1 Market size and forecast, by Components
- 7.3.5.1.2 Market size and forecast, by Application
- 7.3.5.1.3 Market size and forecast, by End User
- 7.3.5.2 France
- 7.3.5.2.1 Market size and forecast, by Components
- 7.3.5.2.2 Market size and forecast, by Application
- 7.3.5.2.3 Market size and forecast, by End User
- 7.3.5.3 UK
- 7.3.5.3.1 Market size and forecast, by Components
- 7.3.5.3.2 Market size and forecast, by Application
- 7.3.5.3.3 Market size and forecast, by End User
- 7.3.5.4 Italy
- 7.3.5.4.1 Market size and forecast, by Components
- 7.3.5.4.2 Market size and forecast, by Application
- 7.3.5.4.3 Market size and forecast, by End User
- 7.3.5.5 Spain
- 7.3.5.5.1 Market size and forecast, by Components
- 7.3.5.5.2 Market size and forecast, by Application
- 7.3.5.5.3 Market size and forecast, by End User
- 7.3.5.6 Rest of Europe
- 7.3.5.6.1 Market size and forecast, by Components
- 7.3.5.6.2 Market size and forecast, by Application
- 7.3.5.6.3 Market size and forecast, by End User
- 7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Components
- 7.4.2.1 Asia-Pacific Data Sets Real World Evidence Solutions Market by Type
- 7.4.3 Asia-Pacific Market size and forecast, by Application
- 7.4.3.1 Asia-Pacific Drug Development and Approvals Real World Evidence Solutions Market by Type
- 7.4.4 Asia-Pacific Market size and forecast, by End User
- 7.4.5 Asia-Pacific Market size and forecast, by country
- 7.4.5.1 Japan
- 7.4.5.1.1 Market size and forecast, by Components
- 7.4.5.1.2 Market size and forecast, by Application
- 7.4.5.1.3 Market size and forecast, by End User
- 7.4.5.2 China
- 7.4.5.2.1 Market size and forecast, by Components
- 7.4.5.2.2 Market size and forecast, by Application
- 7.4.5.2.3 Market size and forecast, by End User
- 7.4.5.3 Australia
- 7.4.5.3.1 Market size and forecast, by Components
- 7.4.5.3.2 Market size and forecast, by Application
- 7.4.5.3.3 Market size and forecast, by End User
- 7.4.5.4 India
- 7.4.5.4.1 Market size and forecast, by Components
- 7.4.5.4.2 Market size and forecast, by Application
- 7.4.5.4.3 Market size and forecast, by End User
- 7.4.5.5 South Korea
- 7.4.5.5.1 Market size and forecast, by Components
- 7.4.5.5.2 Market size and forecast, by Application
- 7.4.5.5.3 Market size and forecast, by End User
- 7.4.5.6 Rest Of Asia Pacifc
- 7.4.5.6.1 Market size and forecast, by Components
- 7.4.5.6.2 Market size and forecast, by Application
- 7.4.5.6.3 Market size and forecast, by End User
- 7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Components
- 7.5.2.1 LAMEA Data Sets Real World Evidence Solutions Market by Type
- 7.5.3 LAMEA Market size and forecast, by Application
- 7.5.3.1 LAMEA Drug Development and Approvals Real World Evidence Solutions Market by Type
- 7.5.4 LAMEA Market size and forecast, by End User
- 7.5.5 LAMEA Market size and forecast, by country
- 7.5.5.1 Brazil
- 7.5.5.1.1 Market size and forecast, by Components
- 7.5.5.1.2 Market size and forecast, by Application
- 7.5.5.1.3 Market size and forecast, by End User
- 7.5.5.2 Saudi Arabia
- 7.5.5.2.1 Market size and forecast, by Components
- 7.5.5.2.2 Market size and forecast, by Application
- 7.5.5.2.3 Market size and forecast, by End User
- 7.5.5.3 South Africa
- 7.5.5.3.1 Market size and forecast, by Components
- 7.5.5.3.2 Market size and forecast, by Application
- 7.5.5.3.3 Market size and forecast, by End User
- 7.5.5.4 Rest of LAMEA
- 7.5.5.4.1 Market size and forecast, by Components
- 7.5.5.4.2 Market size and forecast, by Application
- 7.5.5.4.3 Market size and forecast, by End User
- CHAPTER 8: COMPANY LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments
- CHAPTER 9: COMPANY PROFILES
- 9.1 Clinigen Group plc
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
- 9.2 Cognizant Technology Solutions Corp.
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
- 9.3 Clarivate plc
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
- 9.4 IBM Corporation
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
- 9.5 Elevance Health Inc
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
- 9.6 Flatiron Health
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
- 9.7 ICON PLC
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
- 9.8 IQVIA
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
- 9.9 Medpace Holding Corporation
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
- 9.10 Oracle Corporation
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
- 9.11 Parexel International Corporation
- 9.11.1 Company overview
- 9.11.2 Company snapshot
- 9.11.3 Operating business segments
- 9.11.4 Product portfolio
- 9.11.5 Business performance
- 9.11.6 Key strategic moves and developments
- 9.12 Perkin Elmer Inc
- 9.12.1 Company overview
- 9.12.2 Company snapshot
- 9.12.3 Operating business segments
- 9.12.4 Product portfolio
- 9.12.5 Business performance
- 9.12.6 Key strategic moves and developments
- 9.13 SAS Institute Inc
- 9.13.1 Company overview
- 9.13.2 Company snapshot
- 9.13.3 Operating business segments
- 9.13.4 Product portfolio
- 9.13.5 Business performance
- 9.13.6 Key strategic moves and developments
- 9.14 Symphony Innovation LLC
- 9.14.1 Company overview
- 9.14.2 Company snapshot
- 9.14.3 Operating business segments
- 9.14.4 Product portfolio
- 9.14.5 Business performance
- 9.14.6 Key strategic moves and developments
- 9.15 Syneos Health Inc
- 9.15.1 Company overview
- 9.15.2 Company snapshot
- 9.15.3 Operating business segments
- 9.15.4 Product portfolio
- 9.15.5 Business performance
- 9.15.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENTS, 2021-2031 ($MILLION)
- TABLE 2. REAL WORLD EVIDENCE SOLUTIONS MARKET, FOR DATA SETS, BY REGION, 2021-2031 ($MILLION)
- TABLE 3. REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 4. GLOBAL DATA SETS REAL WORLD EVIDENCE SOLUTIONS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 5. REAL WORLD EVIDENCE SOLUTIONS MARKET, FOR DISPARATE DATASETS, BY REGION, 2021-2031 ($MILLION)
- TABLE 6. REAL WORLD EVIDENCE SOLUTIONS MARKET, FOR INTEGRATED DATASETS, BY REGION, 2021-2031 ($MILLION)
- TABLE 7. REAL WORLD EVIDENCE SOLUTIONS MARKET, FOR CONSULTING SERVICES, BY REGION, 2021-2031 ($MILLION)
- TABLE 8. REAL WORLD EVIDENCE SOLUTIONS MARKET FOR CONSULTING SERVICES, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 9. GLOBAL REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 10. REAL WORLD EVIDENCE SOLUTIONS MARKET, FOR MARKET ACCESS AND REIMBURSEMENT COVERAGE DECISIONS, BY REGION, 2021-2031 ($MILLION)
- TABLE 11. REAL WORLD EVIDENCE SOLUTIONS MARKET FOR MARKET ACCESS AND REIMBURSEMENT COVERAGE DECISIONS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 12. REAL WORLD EVIDENCE SOLUTIONS MARKET, FOR DRUG DEVELOPMENT AND APPROVALS, BY REGION, 2021-2031 ($MILLION)
- TABLE 13. REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT AND APPROVALS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 14. GLOBAL DRUG DEVELOPMENT AND APPROVALS REAL WORLD EVIDENCE SOLUTIONS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 15. REAL WORLD EVIDENCE SOLUTIONS MARKET, FOR ONCOLOGY, BY REGION, 2021-2031 ($MILLION)
- TABLE 16. REAL WORLD EVIDENCE SOLUTIONS MARKET, FOR NEUROLOGY, BY REGION, 2021-2031 ($MILLION)
- TABLE 17. REAL WORLD EVIDENCE SOLUTIONS MARKET, FOR IMMUNOLOGY, BY REGION, 2021-2031 ($MILLION)
- TABLE 18. REAL WORLD EVIDENCE SOLUTIONS MARKET, FOR CARDIOVASCULAR DISEASES, BY REGION, 2021-2031 ($MILLION)
- TABLE 19. REAL WORLD EVIDENCE SOLUTIONS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 20. REAL WORLD EVIDENCE SOLUTIONS MARKET, FOR POST MARKET SURVEILLANCE, BY REGION, 2021-2031 ($MILLION)
- TABLE 21. REAL WORLD EVIDENCE SOLUTIONS MARKET FOR POST MARKET SURVEILLANCE, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 22. REAL WORLD EVIDENCE SOLUTIONS MARKET, FOR MEDICAL DEVICE DEVELOPMENT AND APPROVALS, BY REGION, 2021-2031 ($MILLION)
- TABLE 23. REAL WORLD EVIDENCE SOLUTIONS MARKET FOR MEDICAL DEVICE DEVELOPMENT AND APPROVALS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 24. REAL WORLD EVIDENCE SOLUTIONS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 25. REAL WORLD EVIDENCE SOLUTIONS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 26. GLOBAL REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 27. REAL WORLD EVIDENCE SOLUTIONS MARKET, FOR PHARMACEUTICAL AND MEDICAL DEVICE COMPANIES, BY REGION, 2021-2031 ($MILLION)
- TABLE 28. REAL WORLD EVIDENCE SOLUTIONS MARKET FOR PHARMACEUTICAL AND MEDICAL DEVICE COMPANIES, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 29. REAL WORLD EVIDENCE SOLUTIONS MARKET, FOR HEALTHCARE PAYERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 30. REAL WORLD EVIDENCE SOLUTIONS MARKET FOR HEALTHCARE PAYERS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 31. REAL WORLD EVIDENCE SOLUTIONS MARKET, FOR HEALTHCARE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 32. REAL WORLD EVIDENCE SOLUTIONS MARKET FOR HEALTHCARE PROVIDERS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 33. REAL WORLD EVIDENCE SOLUTIONS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 34. REAL WORLD EVIDENCE SOLUTIONS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 35. REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REGION, 2021-2031 ($MILLION)
- TABLE 36. NORTH AMERICA REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENTS, 2021-2031 ($MILLION)
- TABLE 37. NORTH AMERICA DATA SETS REAL WORLD EVIDENCE SOLUTIONS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 38. NORTH AMERICA REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 39. NORTH AMERICA DRUG DEVELOPMENT AND APPROVALS REAL WORLD EVIDENCE SOLUTIONS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 40. NORTH AMERICA REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 41. NORTH AMERICA REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 42. U.S. REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENTS, 2021-2031 ($MILLION)
- TABLE 43. U.S. REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 44. U.S. REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 45. CANADA REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENTS, 2021-2031 ($MILLION)
- TABLE 46. CANADA REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 47. CANADA REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 48. MEXICO REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENTS, 2021-2031 ($MILLION)
- TABLE 49. MEXICO REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 50. MEXICO REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 51. EUROPE REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENTS, 2021-2031 ($MILLION)
- TABLE 52. EUROPE DATA SETS REAL WORLD EVIDENCE SOLUTIONS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 53. EUROPE REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 54. EUROPE DRUG DEVELOPMENT AND APPROVALS REAL WORLD EVIDENCE SOLUTIONS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 55. EUROPE REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 56. EUROPE REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 57. GERMANY REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENTS, 2021-2031 ($MILLION)
- TABLE 58. GERMANY REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 59. GERMANY REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 60. FRANCE REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENTS, 2021-2031 ($MILLION)
- TABLE 61. FRANCE REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 62. FRANCE REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 63. UK REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENTS, 2021-2031 ($MILLION)
- TABLE 64. UK REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 65. UK REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 66. ITALY REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENTS, 2021-2031 ($MILLION)
- TABLE 67. ITALY REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 68. ITALY REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 69. SPAIN REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENTS, 2021-2031 ($MILLION)
- TABLE 70. SPAIN REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 71. SPAIN REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 72. REST OF EUROPE REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENTS, 2021-2031 ($MILLION)
- TABLE 73. REST OF EUROPE REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 74. REST OF EUROPE REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 75. ASIA-PACIFIC REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENTS, 2021-2031 ($MILLION)
- TABLE 76. ASIA-PACIFIC DATA SETS REAL WORLD EVIDENCE SOLUTIONS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 77. ASIA-PACIFIC REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 78. ASIA-PACIFIC DRUG DEVELOPMENT AND APPROVALS REAL WORLD EVIDENCE SOLUTIONS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 79. ASIA-PACIFIC REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 80. ASIA-PACIFIC REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 81. JAPAN REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENTS, 2021-2031 ($MILLION)
- TABLE 82. JAPAN REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 83. JAPAN REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 84. CHINA REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENTS, 2021-2031 ($MILLION)
- TABLE 85. CHINA REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 86. CHINA REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 87. AUSTRALIA REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENTS, 2021-2031 ($MILLION)
- TABLE 88. AUSTRALIA REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 89. AUSTRALIA REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 90. INDIA REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENTS, 2021-2031 ($MILLION)
- TABLE 91. INDIA REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 92. INDIA REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 93. SOUTH KOREA REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENTS, 2021-2031 ($MILLION)
- TABLE 94. SOUTH KOREA REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 95. SOUTH KOREA REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 96. REST OF ASIA PACIFC REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENTS, 2021-2031 ($MILLION)
- TABLE 97. REST OF ASIA PACIFC REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 98. REST OF ASIA PACIFC REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 99. LAMEA REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENTS, 2021-2031 ($MILLION)
- TABLE 100. LAMEA DATA SETS REAL WORLD EVIDENCE SOLUTIONS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 101. LAMEA REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 102. LAMEA DRUG DEVELOPMENT AND APPROVALS REAL WORLD EVIDENCE SOLUTIONS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 103. LAMEA REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 104. LAMEA REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 105. BRAZIL REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENTS, 2021-2031 ($MILLION)
- TABLE 106. BRAZIL REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 107. BRAZIL REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 108. SAUDI ARABIA REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENTS, 2021-2031 ($MILLION)
- TABLE 109. SAUDI ARABIA REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 110. SAUDI ARABIA REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 111. SOUTH AFRICA REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENTS, 2021-2031 ($MILLION)
- TABLE 112. SOUTH AFRICA REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 113. SOUTH AFRICA REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 114. REST OF LAMEA REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENTS, 2021-2031 ($MILLION)
- TABLE 115. REST OF LAMEA REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 116. REST OF LAMEA REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 117.CLINIGEN GROUP PLC: COMPANY SNAPSHOT
- TABLE 118.CLINIGEN GROUP PLC: OPERATING SEGMENTS
- TABLE 119.CLINIGEN GROUP PLC: PRODUCT PORTFOLIO
- TABLE 120.CLINIGEN GROUP PLC: NET SALES,
- TABLE 121.CLINIGEN GROUP PLC: KEY STRATERGIES
- TABLE 122.COGNIZANT TECHNOLOGY SOLUTIONS CORP.: COMPANY SNAPSHOT
- TABLE 123.COGNIZANT TECHNOLOGY SOLUTIONS CORP.: OPERATING SEGMENTS
- TABLE 124.COGNIZANT TECHNOLOGY SOLUTIONS CORP.: PRODUCT PORTFOLIO
- TABLE 125.COGNIZANT TECHNOLOGY SOLUTIONS CORP.: NET SALES,
- TABLE 126.COGNIZANT TECHNOLOGY SOLUTIONS CORP.: KEY STRATERGIES
- TABLE 127.CLARIVATE PLC: COMPANY SNAPSHOT
- TABLE 128.CLARIVATE PLC: OPERATING SEGMENTS
- TABLE 129.CLARIVATE PLC: PRODUCT PORTFOLIO
- TABLE 130.CLARIVATE PLC: NET SALES,
- TABLE 131.CLARIVATE PLC: KEY STRATERGIES
- TABLE 132.IBM CORPORATION: COMPANY SNAPSHOT
- TABLE 133.IBM CORPORATION: OPERATING SEGMENTS
- TABLE 134.IBM CORPORATION: PRODUCT PORTFOLIO
- TABLE 135.IBM CORPORATION: NET SALES,
- TABLE 136.IBM CORPORATION: KEY STRATERGIES
- TABLE 137.ELEVANCE HEALTH INC: COMPANY SNAPSHOT
- TABLE 138.ELEVANCE HEALTH INC: OPERATING SEGMENTS
- TABLE 139.ELEVANCE HEALTH INC: PRODUCT PORTFOLIO
- TABLE 140.ELEVANCE HEALTH INC: NET SALES,
- TABLE 141.ELEVANCE HEALTH INC: KEY STRATERGIES
- TABLE 142.FLATIRON HEALTH: COMPANY SNAPSHOT
- TABLE 143.FLATIRON HEALTH: OPERATING SEGMENTS
- TABLE 144.FLATIRON HEALTH: PRODUCT PORTFOLIO
- TABLE 145.FLATIRON HEALTH: NET SALES,
- TABLE 146.FLATIRON HEALTH: KEY STRATERGIES
- TABLE 147.ICON PLC: COMPANY SNAPSHOT
- TABLE 148.ICON PLC: OPERATING SEGMENTS
- TABLE 149.ICON PLC: PRODUCT PORTFOLIO
- TABLE 150.ICON PLC: NET SALES,
- TABLE 151.ICON PLC: KEY STRATERGIES
- TABLE 152.IQVIA: COMPANY SNAPSHOT
- TABLE 153.IQVIA: OPERATING SEGMENTS
- TABLE 154.IQVIA: PRODUCT PORTFOLIO
- TABLE 155.IQVIA: NET SALES,
- TABLE 156.IQVIA: KEY STRATERGIES
- TABLE 157.MEDPACE HOLDING CORPORATION: COMPANY SNAPSHOT
- TABLE 158.MEDPACE HOLDING CORPORATION: OPERATING SEGMENTS
- TABLE 159.MEDPACE HOLDING CORPORATION: PRODUCT PORTFOLIO
- TABLE 160.MEDPACE HOLDING CORPORATION: NET SALES,
- TABLE 161.MEDPACE HOLDING CORPORATION: KEY STRATERGIES
- TABLE 162.ORACLE CORPORATION: COMPANY SNAPSHOT
- TABLE 163.ORACLE CORPORATION: OPERATING SEGMENTS
- TABLE 164.ORACLE CORPORATION: PRODUCT PORTFOLIO
- TABLE 165.ORACLE CORPORATION: NET SALES,
- TABLE 166.ORACLE CORPORATION: KEY STRATERGIES
- TABLE 167.PAREXEL INTERNATIONAL CORPORATION: COMPANY SNAPSHOT
- TABLE 168.PAREXEL INTERNATIONAL CORPORATION: OPERATING SEGMENTS
- TABLE 169.PAREXEL INTERNATIONAL CORPORATION: PRODUCT PORTFOLIO
- TABLE 170.PAREXEL INTERNATIONAL CORPORATION: NET SALES,
- TABLE 171.PAREXEL INTERNATIONAL CORPORATION: KEY STRATERGIES
- TABLE 172.PERKIN ELMER INC: COMPANY SNAPSHOT
- TABLE 173.PERKIN ELMER INC: OPERATING SEGMENTS
- TABLE 174.PERKIN ELMER INC: PRODUCT PORTFOLIO
- TABLE 175.PERKIN ELMER INC: NET SALES,
- TABLE 176.PERKIN ELMER INC: KEY STRATERGIES
- TABLE 177.SAS INSTITUTE INC: COMPANY SNAPSHOT
- TABLE 178.SAS INSTITUTE INC: OPERATING SEGMENTS
- TABLE 179.SAS INSTITUTE INC: PRODUCT PORTFOLIO
- TABLE 180.SAS INSTITUTE INC: NET SALES,
- TABLE 181.SAS INSTITUTE INC: KEY STRATERGIES
- TABLE 182.SYMPHONY INNOVATION LLC: COMPANY SNAPSHOT
- TABLE 183.SYMPHONY INNOVATION LLC: OPERATING SEGMENTS
- TABLE 184.SYMPHONY INNOVATION LLC: PRODUCT PORTFOLIO
- TABLE 185.SYMPHONY INNOVATION LLC: NET SALES,
- TABLE 186.SYMPHONY INNOVATION LLC: KEY STRATERGIES
- TABLE 187.SYNEOS HEALTH INC: COMPANY SNAPSHOT
- TABLE 188.SYNEOS HEALTH INC: OPERATING SEGMENTS
- TABLE 189.SYNEOS HEALTH INC: PRODUCT PORTFOLIO
- TABLE 190.SYNEOS HEALTH INC: NET SALES,
- TABLE 191.SYNEOS HEALTH INC: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1.REAL WORLD EVIDENCE SOLUTIONS MARKET SEGMENTATION
- FIGURE 2.REAL WORLD EVIDENCE SOLUTIONS MARKET,2021-2031
- FIGURE 3.REAL WORLD EVIDENCE SOLUTIONS MARKET,2021-2031
- FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 5.PORTER FIVE-1
- FIGURE 6.PORTER FIVE-2
- FIGURE 7.PORTER FIVE-3
- FIGURE 8.PORTER FIVE-4
- FIGURE 9.PORTER FIVE-5
- FIGURE 10.TOP PLAYER POSITIONING
- FIGURE 11.REAL WORLD EVIDENCE SOLUTIONS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 12.REAL WORLD EVIDENCE SOLUTIONS MARKET,BY COMPONENTS,2021(%)
- FIGURE 13.COMPARATIVE SHARE ANALYSIS OF DATA SETS REAL WORLD EVIDENCE SOLUTIONS MARKET,2021-2031(%)
- FIGURE 14.COMPARATIVE SHARE ANALYSIS OF CONSULTING SERVICES REAL WORLD EVIDENCE SOLUTIONS MARKET,2021-2031(%)
- FIGURE 15.REAL WORLD EVIDENCE SOLUTIONS MARKET,BY APPLICATION,2021(%)
- FIGURE 16.COMPARATIVE SHARE ANALYSIS OF MARKET ACCESS AND REIMBURSEMENT COVERAGE DECISIONS REAL WORLD EVIDENCE SOLUTIONS MARKET,2021-2031(%)
- FIGURE 17.COMPARATIVE SHARE ANALYSIS OF DRUG DEVELOPMENT AND APPROVALS REAL WORLD EVIDENCE SOLUTIONS MARKET,2021-2031(%)
- FIGURE 18.COMPARATIVE SHARE ANALYSIS OF POST MARKET SURVEILLANCE REAL WORLD EVIDENCE SOLUTIONS MARKET,2021-2031(%)
- FIGURE 19.COMPARATIVE SHARE ANALYSIS OF MEDICAL DEVICE DEVELOPMENT AND APPROVALS REAL WORLD EVIDENCE SOLUTIONS MARKET,2021-2031(%)
- FIGURE 20.COMPARATIVE SHARE ANALYSIS OF OTHERS REAL WORLD EVIDENCE SOLUTIONS MARKET,2021-2031(%)
- FIGURE 21.REAL WORLD EVIDENCE SOLUTIONS MARKET,BY END USER,2021(%)
- FIGURE 22.COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL AND MEDICAL DEVICE COMPANIES REAL WORLD EVIDENCE SOLUTIONS MARKET,2021-2031(%)
- FIGURE 23.COMPARATIVE SHARE ANALYSIS OF HEALTHCARE PAYERS REAL WORLD EVIDENCE SOLUTIONS MARKET,2021-2031(%)
- FIGURE 24.COMPARATIVE SHARE ANALYSIS OF HEALTHCARE PROVIDERS REAL WORLD EVIDENCE SOLUTIONS MARKET,2021-2031(%)
- FIGURE 25.COMPARATIVE SHARE ANALYSIS OF OTHERS REAL WORLD EVIDENCE SOLUTIONS MARKET,2021-2031(%)
- FIGURE 26.REAL WORLD EVIDENCE SOLUTIONS MARKET BY REGION,2021
- FIGURE 27.U.S. REAL WORLD EVIDENCE SOLUTIONS MARKET,2021-2031($MILLION)
- FIGURE 28.CANADA REAL WORLD EVIDENCE SOLUTIONS MARKET,2021-2031($MILLION)
- FIGURE 29
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook